In situ genetic engineering of tumors for long-lasting and systemic immunotherapy [Engineering]
Cancer immunotherapy has been the subject of extensive research, but highly effective and broadly applicable methods remain elusive. Moreover, a general approach to engender endogenous patient-specific cellular therapy, without the need for a priori knowledge of tumor antigen, ex vivo cellular manipulation, or cellular manufacture, could dramatically reduce costs and...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Stephany Y. Tzeng, Kisha K. Patel, David R. Wilson, Randall A. Meyer, Kelly R. Rhodes, Jordan J. Green Tags: Biological Sciences Source Type: research
More News: Academies | Cancer | Cancer & Oncology | Genetics | Immunotherapy | Jordan Health | Middle East Health | Science